A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: Intermediate dose cytarabine (2 × 1 g/m 2 on days 1, 3, and 5)

Clinical Cancer Research

Volumn 10, Issue 12 I, 2004, Pages 3965-3971

  Sperr, Wolfgang R ^a   Piribauer, Maria ^a   Wimazal, Friedrich ^a   Fonatsch, Christa ^a   Thalhammer Scherrer, Renate ^a   Schwarzinger, Ilse ^a   Geissler, Klaus ^a   Knöbl, Paul ^a   Jäger, Ulrich ^a   Lechner, Klaus ^a   Valent, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONSOLIDATION THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GERIATRIC PATIENT; HEART FAILURE; HUMAN; INTERMEDIATE DRUG DOSE; KARYOTYPE; LIVER TOXICITY; MALE; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; RASH;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; KARYOTYPING; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 3042538402     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0185     Document Type: Article

References (41)

1. Peterson BA, Bloomfield CD. Treatment of acute nonlymphocytic leukemia in elderly patients: a prospective study of intensive chemotherapy. Cancer (Phila.) 1977;40:647-52.
2. Brincker H. Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission. Cancer Treat Rep 1985;69:5-11.
3. Baudard M, Marie JP, Cadiou M, Viguie F, Zittoun R. Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. Br J Haematol 1994;86:82-91.
4. Rowe JM, Andersen JW, Mazza JJ, et al. Randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995;86:457-62.
5. Buchner T, Hiddemann W, Berdel W, et al. Acute myeloid leukemia: treatment over 60. Rev Clin Exp Hematol 2002;6:46-59.
6. Foon KA, Zighelboim J, Yale C, Gale RP. Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia. Blood 1981;58:467-70.
7. Sebban C, Archimbaud E, Coiffier B, et al. Treatment of acute myeloid leukemia in elderly patients. A retrospective study. Cancer (Phila.) 1988;61:227-31.
8. Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65 + years with acute myeloid leukemia: a randomized Phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989;7:1268-74.
9. Löwenberg B. Treatment of the elderly patient with acute myeloid leukaemia. Baillieres Clin Haematol 1996;9:147-59.
10. Büchner T, Hiddemann W, Schoch C, Haferlach T, Sauerland MC, Heinecke A. Acute myeloid leukaemia (AML): treatment of the older patient. Best Pract Res Clin Haematol 2001;14:139-51.
11. Keating MJ, McCredie KB, Benjamin RS, et al. Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP). Blood 1981;58:584-91.
12. Liu Yin JA, Johnson PR, Davies JM, Flanagan NG, Gorst DW, Lewis MJ. Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia. Br J Haematol 1991;79:415-20.
13. Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wormann B, Buchner T. Management of acute myeloid leukemia in elderly patients. J Clin Oncol 1999;17:3569-76.
14. Baudard M, Beauchamp-Nicoud A, Delmer A, et al. Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period. Leukemia (Baltimore) 1999;13:1481-90.
15. Rowe JM. Treatment of acute myelogenous leukemia in older adults. Leukemia (Baltimore) 2000;14:480-7.
16. Pinto A, Zagonel V, Ferrara F. Acute myeloid leukemia in the elderly: biology and therapeutic strategies. Crit Rev Oncol Hematol 2001;39:275-287.
17. Embury SH, Elias L, Heller PH, Hood CE, Greenberg PL, Schrier SL. Remission maintenance therapy in acute myelogenous leukemia. West J Med 1977;126:267-72.
18. Buchner T, Urbanitz D, Hiddemann W, et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985;3:1583-9.
19. Cassileth PA, Harrington DP, Hines JD, et al. Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol 1988;6:583-7.
20. Schiller G, Gajewski J, Territo M, et al. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 1992;80:2977-82.
21. Cassileth PA, Lynch E, Hines JD, et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1972;79:1924-30.
22. Estey EH. Therapeutic options for acute myelogenous leukemia. Cancer (Phila.) 2001;92:1059-73.
23. Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1990;8:272-9.
24. Bassan R, Buelli M, Viero P, Minotti C, Barbui T. The management of acute myelogenous leukemia in the elderly: 10-year experience in 118 patients. Hematol Oncol 1992;10:251-60.
25. Johnson PR, Hunt LP, Yin JA. Prognostic factors in elderly patients with acute myeloid leukaemia: development of a model to predict survival. Br J Haematol 1993;85:300-6.
26. Ruutu T, Almqvist A, Hallman H, et al. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group. Leukemia (Baltimore) 1994;8:11-5.
27. Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995;332:1671-7.
28. Stasi R, Venditti A, Del Poeta G, et al. Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: analysis of prognostic factors. Cancer (Phila.) 1996;77:2476-88.
29. Feldman EJ, Seiter K, Damon L, et al. A randomized trial of high-versus standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia (Baltimore) 1997;11:485-9.
30. Archimbaud E, Jehn U, Thomas X, et al. Multicenter randomized Phase II trial of idarubicin versus mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Leukemia (Baltimore) 1999;13:843-9.
31. Stone RM, Berg DT, George SL, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 2001;98:548-53.
32. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903.
33. Archimbaud E, Ottmann OG, Yin JA, et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 1999;94:3694-701.
34. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451-8.
35. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620-5.
36. Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 1991;78:325-9.
37. Mitelman F, editor. ISCN: an international system for human cytogenetic nomenclature. Basel: S. Karger; 1995.
38. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDRI) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997;89:3323-9.
39. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;15:1519-38.
40. Cheson BD, Bennett JM, Kopecky KJ, et al. Treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-9.
41. Estey EH. How I treat older patients with AML. Blood 2000;96:1670-3.